Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.44 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7578408 | 0.95 | TDP1 (0.46) | TDP1L3MBTL1MAPK1MAPTMEN1 | |
| SCHEMBL7571177 | 0.81 | NPC1 (0.47) | L3MBTL1MAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL16826227 | 0.79 | TDP1 (0.59) | TDP1L3MBTL1MAPK1MAPTMEN1 | |
| SCHEMBL3290933 | 0.79 | TDP1 (0.59) | TDP1L3MBTL1MAPK1MAPTMEN1 | |
| SCHEMBL8332586 | 0.78 | SMN1; SMN2 (0.48) | TDP1MEN1KMT2AALDH1A1NPC1 | |
| SCHEMBL5857539 | 0.78 | TDP1 (0.61) | TDP1L3MBTL1MAPK1MAPTMEN1 | |
| SCHEMBL27694436 | 0.77 | RAB9A (0.51) | L3MBTL1MAPK1MAPTMEN1KMT2A | |
| SCHEMBL5935764 | 0.76 | ALDH1A1 (0.49) | L3MBTL1MAPK1MAPTKMT2AALDH1A1 | |
| SCHEMBL5358230 | 0.76 | ALDH1A1 (0.49) | L3MBTL1MAPK1MAPTKMT2AALDH1A1 | |
| SCHEMBL8073700 | 0.76 | ALDH1A1 (0.39) | L3MBTL1MAPK1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | HORST P.O. WOLF (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6013666-A | ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION | Jew, Sang Sup (KR) | 2000-01-11 | — | — | US | disclosed |
| WO-1998000422-A1 | OXIRANE CARBOXYLIC ACID DERIVATIVE AND ITS MANUFACTURING METHOD | JEW SANG SUP (KR) | 1998-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198382-A1 | Oxiran carboxylic acids for the treatment of diabetes | GPR119, SLC5A2, SLC2A4 | TDP1 4817/4885L3MBTL1 4472/4885MAPK1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.